Mylan Shares Outstanding 2006-2018 | MYL

Mylan shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Mylan shares outstanding for the quarter ending September 30, 2018 were 0.517B, a 3.82% decline year-over-year.
  • Mylan 2017 shares outstanding were 0.537B, a 3.11% increase from 2016.
  • Mylan 2016 shares outstanding were 0.521B, a 4.64% increase from 2015.
  • Mylan 2015 shares outstanding were 0.497B, a 24.97% increase from 2014.
Mylan Annual Shares Outstanding
(Millions of Shares)
2017 537
2016 521
2015 497
2014 398
2013 395
2012 420
2011 439
2010 329
2009 307
2008 304
2007 257
2007 219
2006 234
2005 274
Mylan Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 517
Q2 2018 516
Q1 2018 517
Q4 2017 537
Q3 2017 537
Q2 2017 537
Q1 2017 537
Q4 2016 521
Q3 2016 524
Q2 2016 510
Q1 2016 510
Q4 2015 497
Q3 2015 514
Q2 2015 522
Q1 2015 444
Q4 2014 398
Q3 2014 397
Q2 2014 397
Q1 2014 397
Q4 2013 395
Q3 2013 396
Q2 2013 387
Q1 2013 399
Q4 2012 420
Q3 2012 412
Q2 2012 424
Q1 2012 432
Q4 2011 439
Q3 2011 432
Q2 2011 445
Q1 2011 448
Q4 2010 329
Q3 2010 438
Q2 2010 314
Q1 2010 312
Q4 2009 307
Q3 2009 305
Q2 2009 306
Q1 2009 458
Q4 2008 304
Q3 2008 458
Q2 2008 304
Q1 2008 304
Q4 2007 257
Q3 2007 251
Q2 2007 252
Q1 2007 227
Q4 2006 216
Q3 2006 215
Q2 2006 215
Q1 2006 0
Q4 2005 219
Q3 2005 229
Q2 2005 273
Q1 2005 0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $18.439B $11.908B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $54.860B 9.42
Teva Pharmaceutical Industries (TEVA) Israel $23.927B 7.33
Bausch Health Cos (BHC) Canada $9.314B 6.74
Dr Reddy's Laboratories (RDY) India $5.645B 22.54
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.589B 4.32
Supernus Pharmaceuticals (SUPN) United States $2.357B 22.33
Amphastar Pharmaceuticals (AMPH) United States $0.978B 106.05
Akorn (AKRX) United States $0.853B 0.00
Homology Medicines (FIXX) United States $0.748B 0.00
Assembly Biosciences (ASMB) United States $0.570B 0.00
CymaBay Therapeutics (CBAY) United States $0.536B 0.00
Corium (CORI) United States $0.458B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.451B 0.00
Voyager Therapeutics (VYGR) United States $0.384B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.315B 0.00
Teligent (TLGT) United States $0.170B 0.00
Sol-Gel Technologies (SLGL) Israel $0.135B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.095B 0.00
Aevi Genomic Medicine (GNMX) United States $0.076B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.053B 0.00
Evoke Pharma (EVOK) United States $0.046B 0.00
Acasti Pharma (ACST) Canada $0.042B 0.00
Agile Therapeutics (AGRX) United States $0.032B 0.00
China Pharma Holdings (CPHI) China $0.016B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.008B 0.00